These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3856083)

  • 1. Amsacrine and etoposide induced paralytic ileus in a patient with acute myelomonocytic leukemia.
    Kucuk O; Apostol JV
    J Surg Oncol; 1985 Mar; 28(3):172-3. PubMed ID: 3856083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
    Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
    Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
    Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
    Onkologie; 1984 Aug; 7(4):214-6. PubMed ID: 6384864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospects of new chemotherapies].
    Sculier JP; Klastersky J
    Rev Med Brux; 1982 Oct; 3(8):519-27. PubMed ID: 6897459
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
    Marit G; David B; Reiffers J; Broustet A
    Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
    Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
    Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
    Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amsacrine (AMSA).
    Issell BF
    Cancer Treat Rev; 1980 Jun; 7(2):73-83. PubMed ID: 6931632
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
    Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Büchner T
    Onkologie; 1985 Jun; 8(3):181-4. PubMed ID: 3895100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
    Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
    J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
    Boccia R; Zighelboim J; Champlin RE; Kim CC; Gale RP
    Med Pediatr Oncol; 1984; 12(3):178-9. PubMed ID: 6587178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide in the management of leukemia: a review.
    Bishop JF
    Semin Oncol; 1991 Feb; 18(1 Suppl 2):62-9. PubMed ID: 1992536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Fouillard L; Labopin M; Meloni G; Polge E; Gorin NC; Frassoni F
    Haematologica; 2004 Jan; 89(1):107-8. PubMed ID: 14754615
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
    Abrams RA; Hanson G; Hansen RM; Anderson T
    Cancer Treat Rep; 1986 Apr; 70(4):535. PubMed ID: 3754490
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of amsacrine gluconate in refractory leukemia.
    Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide: fifteen years experience.
    Bernasconi C
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():52-5. PubMed ID: 2653518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.